Inc. (NARI) has reached a new 52-week high, with its stock price climbing to $79.7, marking a significant milestone for the ...

Monteverde & Associates PC (the 'M&A Class Action Firm'), has recovered millions of dollars for shareholders and is ...

Inari Medical has a 12 month low of $36.73 and a 12 month high of $79.69. Insider Buying and Selling at Inari Medical In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of the stock ...

In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

On Tuesday, BTIG analysts downgraded Inari Medical (TASE:PMCN) Inc. (NASDAQ: NARI) stock rating from Buy to Neutral. The decision followed the recent announcement that Stryker (NYSE: SYK) has entered ...

On Tuesday, BTIG analysts downgraded Inari Medical (TASE:PMCN) Inc. (NASDAQ: NARI) stock rating from Buy to Neutral. The decision followed the recent announcement that Stryker (NYSE: SYK ...

Smith Collection / Gado / Getty Images Shares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality. Stryker will ...

Stryker plans to acquire Inari Medical in a deal valued at $4.9 billion and designed to strength its position in the peripheral vascular market. The deal, announced Monday and approved by both ...

On Tuesday, Baird analysts adjusted their stance on Inari Medical (TASE:PMCN) Inc. (NASDAQ:NARI), downgrading the stock from Outperform to Neutral and slightly reducing the price target to $80 from ...

On Tuesday, Baird analysts adjusted their stance on Inari Medical (TASE:PMCN) Inc. (NASDAQ:NARI), downgrading the stock from Outperform to Neutral and slightly reducing the price target to $80 ...

Investing.com -- Inari Medical Inc (NASDAQ:NARI) shares surged sharply after Stryker (NYSE:SYK) announced that it would acquire the medical device maker in an all-cash deal valued at $4.9 billion ...

The medical device maker plans to buy all of Inari’s common stock for $80 a share, representing a total fully diluted equity value of about $4.9 billion.